Certara, Inc. $CERT Position Boosted by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP raised its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 51.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 403,385 shares of the company’s stock after acquiring an additional 136,325 shares during the period. Certara makes up 1.3% of Advantage Alpha Capital Partners LP’s holdings, making the stock its 21st largest position. Advantage Alpha Capital Partners LP owned approximately 0.25% of Certara worth $4,720,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Teacher Retirement System of Texas raised its stake in shares of Certara by 25.3% during the second quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after purchasing an additional 1,145,554 shares in the last quarter. Select Equity Group L.P. increased its stake in Certara by 534.5% during the 1st quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company’s stock valued at $10,836,000 after buying an additional 922,007 shares during the period. Pier Capital LLC acquired a new stake in shares of Certara in the 2nd quarter worth approximately $7,809,000. Ameriprise Financial Inc. boosted its holdings in shares of Certara by 13.6% in the first quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock valued at $42,526,000 after acquiring an additional 515,911 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Certara during the first quarter valued at approximately $4,950,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CERT. Barclays decreased their price target on Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Craig Hallum initiated coverage on Certara in a report on Monday, September 29th. They set a “buy” rating and a $16.00 target price on the stock. UBS Group cut their price target on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Zacks Research raised shares of Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, Redburn Partners set a $10.00 target price on shares of Certara in a report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Certara has a consensus rating of “Moderate Buy” and an average target price of $13.82.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares in the company, valued at $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.33% of the stock is currently owned by company insiders.

Certara Price Performance

NASDAQ CERT opened at $9.14 on Friday. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 1 year low of $8.02 and a 1 year high of $15.69. The company has a market cap of $1.46 billion, a PE ratio of 130.57 and a beta of 1.44. The stock’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $11.06.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same period last year, the firm posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.